Eosinophilic asthma<unk>  was first used for eosinophilic asthma in 2008. In a 106-patient, phase II clinical trial, the researchers showed<unk>  was effective in reducing sputum eosinophils. Furthermore, the patients receiving<unk>  showed improvements in airway function, and a general trend toward greater asthma control than those receiving placebo was observed. A large, 981-patient, phase III clinical trial showed that<unk>  was effective at improving lung function, asthma control, and quality of life in comparison to placebo. These results led to the FDA approval for the maintenance treatment of severe asthma in patients aged 18 years and older, with an eosinophilic phenotype on March 23, 2016.
Reslizumab
Brolucizumab
Inebilizumab
Crizanlizumab
Tocilizumab
Risankizumab
Natalizumab
Ravulizumab